In addition, CTCs are being gradually employed in the detection of mutations and rearrangements in common targeted genes (EGFR, ALK, KRAS, etc.)in tumor patients [13], and can indicate the effect of targeted drugs during the treatment of patients with EGFR mutations and incidence of drug resistance [14]. This evidence concerns the gene EGFR and neoplasm.